Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of alpelisib plus endocrine therapy after CDK4/6 inhibitor progression in PIK3CA-mutated HR-positive HER2-negative advanced breast cancer
MOH_2018-11-09_004741Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib in breast cancer (2 cohorts), sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2018-11-09_004741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-09_004741.